MDGL compared with PTCT: revenue, margins and what each company keeps, and the suppliers and customers both name

MDGLMadrigal Pharmaceuticals, Inc.

Mkt capRevenueRevenue

PTCTPTC Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

MDGLMadrigal Pharmaceuticals, Inc.

PTCTPTC Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

MDGL

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±10.5%▼−9.83%×0.93

Q1 FY26±9.2%▲+7.42%×0.80

Feb 19 '26±6.2%▼−11.11%×1.79

Nov 4 '25±12.9%▲+7.83%×0.60

PTCT

1 of 4at or beyond implied

Reportimpliedrealized× implied

Oct 30 '26±12.0%▼−6.97%×0.58

Q2 FY26±11.6%▼−9.94%×0.85

= impliedMDGL realized, solidPTCT realized, hatchedOne scale, both sides: full bar = 15%× = |realized| ÷ impliedSource: market data

Q1 FY26

±9.4%

▲+14.27%

×1.52

Feb 20 '26±4.3%▲+1.09%×0.26

MDGLMadrigal Pharmaceuticals, Inc.

432.96· pre 432.96· delayed

Mkt cap$9.9BRevenue$364MQ2 FY26Revenue$958MFY25

PTCTPTC Therapeutics, Inc.

60.97· pre 60.84· delayed

Pre-marketNov 3 '26delayed

Mkt cap$5.0BRevenue$361MQ2 FY26Revenue$1.7BFY25

Compare

Pre-marketNov 3 '26delayed

MDGLMadrigal Pharmaceuticals, Inc.

PTCTPTC Therapeutics, Inc.

432.96pre 432.96delayed

Price

60.97pre 60.84delayed

$9.9B

Mkt cap

$5.0B

Q2 FY26$364M

Revenue

$361MQ2 FY26

FY25$958M

Revenue

$1.7BFY25

MDGL432.96vsPTCT60.97Pre-marketNov 3 '26delayed